TOP HEADLINES

FEATURED STORY

  • Covance joins trial site group to speed up R&D

    Covance, now a division of LabCorp, has signed a two-year partnership with the Society for Clinical Research Sites, joining a growing list of CROs working to improve communication between sponsors and investigators.

Patheon unloads some assets on the way to an IPO

Contract drugmaker Patheon is getting out of agrochemicals and selling off a manufacturing plant, narrowing its focus on pharmaceutical development as it plots an IPO.

Covance names a new CEO as it adjusts to life with LabCorp

Covance, acquired by LabCorp for about $6 billion earlier this year, has picked former head of R&D Deborah Keller to take the reins as CEO Joseph Herring retires.

Charles River's revenue slips on slumping R&D demand

Charles River Laboratories saw its sales dip in the second quarter, but the early-stage specialist is counting on some recent acquisitions to spur growth for the full year.

PRA boosts its profit forecast after a strong sales quarter

PRA Health Sciences is ticking up its full-year expectations after another quarter of revenue growth, counting on a steady stream of new business.

Icon dials back its guidance after posting modest sales growth

Icon is again reducing its revenue expectations for 2015 but increasing its profit guidance, counting on a big quarter of business wins to balance some sluggish backlog conversion.

MORE NEWS

From Our Sister Sites

FierceAnimalHealth

Veterinary diagnostics maker IDEXX reported on Thursday that its revenues for the second quarter grew 6% year over year to $413 million, as placements of its blood analysis systems hit a record of 900 units for the period. Placements of its Catalyst One next-generation chemistry analyzer skyrocketed 44% to an all-time record of 1,100 units, the company said in a press release announcing the results.

FierceAnimalHealth

Distributor Henry Schein, which is undergoing a major expansion of its animal health business, reported that earnings in the second quarter grew 8% year over year to $123.2 million or $1.46 per diluted share, on sales that rose a half-percent to $2.6 billion.